ArticleTranslational pediatrics2026
Preliminary experience with oral thrombopoietin-receptor agonists, primarily hetrombopag, in pediatric immune thrombocytopenia: a pilot single-center retrospective report.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although thrombopoietin receptor agonists (TPO-RAs) are effective second-line treatments for pediatric immune thrombocytopenia (ITP), real-world data on newer agents like hetrombopag remain scarce. This study aimed to describe a single-center retrospective experience with oral TPO-RAs, predominantly hetrombopag, in children with ITP who were refractory to or relapsed after first-line therapy. Methods: We conducted a single-center retrospective study of 18 children with ITP treated with oral TPO-RAs (hetrombopag, eltrombopag, or avatrombopag) at Qingdao Women and Children's Hospital from January 2023 to June 2024. Platelet counts, bleeding grades, use of rescue therapy, and adverse events (AEs) were extracted from medical records and summarized descriptively; statistical analyses were performed. Results: Platelet counts increased after treatment initiation, with statistically significant differences from baseline at prespecified time points (week 1, month 1, month 3, and month 6; all Holm-adjusted P≤0.005). Bleeding grades (Buchanan & Adix overall grade 0-4) did not show a statistically significant improvement at the group level (P=0.10) or individual level (P=0.056). No statistically significant associations were detected between response and selected baseline factors (age, sex, disease duration, infection status, bleeding at baseline, or antibody status), although the study was underpowered for these analyses. Most recorded AEs were mild to moderate. Conclusions: In this preliminary, pilot-scale hetrombopag-predominant cohort, oral TPO-RA use was associated with increased platelet counts; however, the limited sample size and lack of statistically significant improvement in bleeding scores preclude definitive conclusions regarding the overall clinical utility of these agents beyond their ability to increase platelet counts. Given the retrospective design, heterogeneity of exposure, and limited sample size, the findings are hypothesis-generating and should be confirmed in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.